DE69805846T2 - Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom - Google Patents

Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom

Info

Publication number
DE69805846T2
DE69805846T2 DE69805846T DE69805846T DE69805846T2 DE 69805846 T2 DE69805846 T2 DE 69805846T2 DE 69805846 T DE69805846 T DE 69805846T DE 69805846 T DE69805846 T DE 69805846T DE 69805846 T2 DE69805846 T2 DE 69805846T2
Authority
DE
Germany
Prior art keywords
glaucoma
glc1a
substituted
gene
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69805846T
Other languages
German (de)
English (en)
Other versions
DE69805846D1 (de
Inventor
R. Hellberg
M. Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69805846D1 publication Critical patent/DE69805846D1/de
Publication of DE69805846T2 publication Critical patent/DE69805846T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69805846T 1997-12-19 1998-12-04 Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom Expired - Fee Related DE69805846T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/994,903 US6066671A (en) 1997-12-19 1997-12-19 Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
PCT/US1998/025744 WO1999032104A1 (en) 1997-12-19 1998-12-04 Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glc1a glaucoma

Publications (2)

Publication Number Publication Date
DE69805846D1 DE69805846D1 (de) 2002-07-11
DE69805846T2 true DE69805846T2 (de) 2003-01-16

Family

ID=25541199

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69805846T Expired - Fee Related DE69805846T2 (de) 1997-12-19 1998-12-04 Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom

Country Status (12)

Country Link
US (2) US6066671A (https=)
EP (1) EP1039895B1 (https=)
JP (1) JP2001526218A (https=)
AT (1) ATE218336T1 (https=)
AU (1) AU746075C (https=)
BR (1) BR9813767A (https=)
CA (1) CA2313386A1 (https=)
DE (1) DE69805846T2 (https=)
DK (1) DK1039895T3 (https=)
ES (1) ES2178291T3 (https=)
PT (1) PT1039895E (https=)
WO (1) WO1999032104A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) * 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
WO2003009774A2 (en) 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
AU2002319606B2 (en) 2001-07-23 2006-09-14 Alcon, Inc. Ophthalmic drug delivery device
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
PT1586316E (pt) * 2003-01-21 2008-05-28 Senju Pharma Co Preparação líquida aquosa contendo ácido 2-amino-3-(4- bromobenzoil)fenilacético
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
CN100484528C (zh) * 2003-11-07 2009-05-06 千寿制药株式会社 含有前列腺素的药物组合物
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
DK2026651T3 (da) 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
WO2009073138A2 (en) * 2007-11-30 2009-06-11 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with novel amides
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5565492A (en) 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5093329A (en) 1990-03-12 1992-03-03 Allergan, Inc. Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives
US5270049A (en) 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5627209A (en) 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
US5474985A (en) 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5891913A (en) * 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
US5606043A (en) 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5925673A (en) 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
US5607966A (en) 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
WO1998021180A1 (en) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5599535A (en) 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5750564A (en) 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
DE69633136T2 (de) 1995-12-22 2005-09-01 Alcon Laboratories, Inc., Fort Worth Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US6172109B1 (en) * 1997-03-07 2001-01-09 Alcon Laboratories, Inc. 13-Thia prostaglandins for use in glaucoma therapy
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
SE9803761D0 (sv) 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment

Also Published As

Publication number Publication date
JP2001526218A (ja) 2001-12-18
US6342524B1 (en) 2002-01-29
PT1039895E (pt) 2002-10-31
US6066671A (en) 2000-05-23
WO1999032104A1 (en) 1999-07-01
AU746075B2 (en) 2002-04-11
ATE218336T1 (de) 2002-06-15
CA2313386A1 (en) 1999-07-01
EP1039895B1 (en) 2002-06-05
DE69805846D1 (de) 2002-07-11
BR9813767A (pt) 2000-10-03
ES2178291T3 (es) 2002-12-16
HK1027748A1 (en) 2001-01-23
AU1625999A (en) 1999-07-12
DK1039895T3 (da) 2002-09-23
EP1039895A1 (en) 2000-10-04
AU746075C (en) 2002-10-17

Similar Documents

Publication Publication Date Title
DE69805846T2 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
US6646001B2 (en) Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
DE69132047T2 (de) Gentherapie gegen krankheiten die die zellteilung betreffen
DE602004005617T2 (de) Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
Bartlett et al. Intraocular pressure response to loteprednol etabonate in known steroid responders
DE60302348T2 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
Driot et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert™ intravitreal implantation in rabbits over a 1-year period
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
DE69732049T2 (de) Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika
US5789399A (en) Treatment of pruritus with vitamin D and analogs thereof
DE69807281T2 (de) Difluprednat enthaltende Zusammensetzungen
DE3788004T2 (de) Verwendung von Tetrahydrocortisol in der Therapie von Glaukom.
DE69620393T2 (de) PHARMAZEUTISCHE NICHTINORGANISCHE SALZLÖSUNGEN FÜR ENDONASALE VERABREICHUNG EINEs CALCITONINs
Bartlett et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis
Karp et al. Intracameral anesthesia: a report by the American Academy of Ophthalmology
CN110177556A (zh) 含有熊去氧胆酸的用于预防或治疗视力障碍的组合物
CA2313232A1 (en) Treatment of glc1a glaucoma with non-steroidal glucocorticoid antagonists
EP2200603B1 (de) Osmolyte zur behandlung von allergisch bedingten atemwegserkrankungen
DE69208941T2 (de) Augenpräparate mit verlängerter Freigabe
DE69530510T2 (de) Chinazolinon enthaltende arzneimittel und verfahren zu deren verwendung
US6090798A (en) Treatment of GLC1A glaucoma with glucocorticoid antagonists
JP2022541013A (ja) 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法
EP3049071B1 (de) Prophylaxe und behandlung einer nicht auf einer proteinfaltungsstörung beruhenden neurodegenerativen erkrankung
CN110013498A (zh) 一种含盐酸奥洛他定的滴眼液及其制备方法
DE69923988T2 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta-estern desselben

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee